In today’s recent session, 0.45 million shares of the Adaptive Biotechnologies Corp (NASDAQ:ADPT) have been traded, and its beta is 1.49. Most recently the company’s share price was $8.24, and it changed around $0.79 or 10.56% from the last close, which brings the market valuation of the company to $1.22B. ADPT at last check was trading at a discount to its 52-week high of $7.50, offering almost 8.98% off that amount. The share price’s 52-week low was $2.28, which indicates that the recent value has risen by an impressive 72.33% since then. We note from Adaptive Biotechnologies Corp’s average daily trading volume that its 10-day average is 1.81 million shares, with the 3-month average coming to 1.30 million.
Adaptive Biotechnologies Corp stock received a consensus recommendation rating of Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended ADPT as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight.
Adaptive Biotechnologies Corp (NASDAQ:ADPT) trade information
Instantly ADPT has been showing a green trend so far today with a performance of 10.56% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 8.00 on recent trading daydecreased the stock’s daily price by -3.0%. The company’s shares are currently up 37.39% year-to-date, but still up 35.70% over the last five days. On the other hand, Adaptive Biotechnologies Corp (NASDAQ:ADPT) is 37.97% up in the 30-day period. We can see from the shorts that 9.19 million shares have been sold at a short interest cover period of 8.44 day(s).
The consensus price target as assigned by Wall Street analysts is $14, which translates to bulls needing to increase their stock price by 41.14% from its current value. Analyst projections state that ADPT is forecast to be at a low of $5 and a high of $18.
Adaptive Biotechnologies Corp (ADPT) estimates and forecasts
Adaptive Biotechnologies Corp share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 98.00 percent over the past six months and at a 18.84% annual growth rate that is well above the industry average of 16.50%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -32.91%.
ADPT Dividends
Adaptive Biotechnologies Corp’s next quarterly earnings report is expected to be released in February.
Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.93% of Adaptive Biotechnologies Corp shares, and 93.89% of them are in the hands of institutional investors. The stock currently has a share float of 95.74%. Adaptive Biotechnologies Corp stock is held by 251.0 institutions, with VIKING GLOBAL INVESTORS LP being the largest institutional investor. By 2024-06-30, it held 20.5736% of the shares, which is about 29.99 million shares worth $108.58 million.
RUBRIC CAPITAL MANAGEMENT LP, with 9.603% or 14.0 million shares worth $50.68 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Nov 30, 2024. The former held 10.72 shares worth $88.77 million, making up 7.26% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 4.19 shares worth around $34.71 million, which represents about 2.84% of the total shares outstanding.
